Background: Ayurvedic medicine offers numerous classical formulations for the management of
dermatological disorders (Kushta). Interest in integrating Ayurvedic therapies into evidence-based dermatology is growing, but systematic evaluation has been limited by heterogeneous study designs and variable reporting. Objective: To perform a systematic review of PubMed-indexed clinical evidence (2014–2024) on Ayurvedic formulations used in skin disease, link findings to classical Samhita references, and evaluate efficacy, safety, and research gaps.
Methods: A PRISMA-guided search of PubMed was conducted using keywords combining 'Ayurveda' and dermatological conditions (psoriasis, eczema, acne, vitiligo, wound healing) and individual herbs (curcumin, neem, bakuchi, triphala). From 312 records identified, 28 studies met inclusion criteria (human clinical studies, English). Data were extracted for study design, population, intervention, outcomes (PASI, EASI, lesion counts, repigmentation rates), duration, and adverse events. Results: Evidence from randomized trials, pilot studies, and open-label trials indicates that curcumin (oral/topical) produces clinically meaningful reductions in psoriasis severity (PASI reductions reported 25–60% in several trials and meta-analyses), neem-containing topical formulations reduce acne lesion counts in short-term studies, and Bakuchi (Psoralea corylifolia) preparations show perifollicular repigmentation in small vitiligo cohorts. Triphala-based topical preparations and wound dressings demonstrate improved wound healing metrics in animal models and small clinical reports. Safety concerns reported include contact photosensitivity with bakuchi, possible contamination/adulteration in poorly regulated products, and rare herb-related systemic effects. Conclusions: Several Ayurvedic formulations show promising efficacy signals in dermatological indications. However, heterogeneity in formulations, dosing, and study quality limit firm recommendations. High-quality, standardized randomized controlled trials, phytochemical standardization, and pharmacovigilance are required to translate these therapies into mainstream dermatology.